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Abstract
Background: In HIV infection, uncontrolled immune activation and disease progression is attributed to declining
CD4+CD25+FoxP3+ regulatory T-cell (Treg) numbers. However, qualitative aspects of Treg function in HIV infection,
specifically the balance between Treg cell suppressive potency versus suppressibility of effector cells, remain poorly
understood. This report addresses this issue.
Methodology/Principal Findings: A classic suppression assay to measure CD4+CD45RO+CD25hi Treg cells to suppress the
proliferationofCD4+CD45RO+CD252effectorscells(E)followingCD3/CD28polyclonalstimulation wasemployedtocompare
the suppressive ability of healthy volunteers (N=27) and chronic, asymptomatic, treatment naı ¨ve, HIV-infected subjects
(N=14). HIV-infected subjects displayed significantly elevated Treg-mediated suppression compared to healthy volunteers
(p=0.0047). Cross-over studies comparing Treg cell potency from HIV-infected versus control subjects to suppress the
proliferation of a given population of allogeneic effector cells demonstrated increased sensitivity of CD4+CD252 effector cells
from HIV-infected subjects to be suppressed, associated with reduced production of the Treg counter-regulatory cytokine, IL-
17, rather than an increase in the suppressive potential of their CD4+CD25+ Treg cells. However, compared to controls, HIV+
subjectshadsignificantlyfewerabsolute numbersofcirculatingCD4+CD25+FoxP3+ Tregcells.Invitrostudieshighlightedthat
one mechanism for this loss could be the preferential infection of Treg cells by HIV.
Conclusions/Significance: Together, novel data is provided to support the contention that elevated Treg-mediated
suppression may be a natural host response to HIV infection
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Introduction
A subpopulation of CD4+ T lymphocytes called Regulatory T
cells (Treg cells) has attracted a significant amount of interest due
to their ability to negatively regulate immune responses. In
humans, this population which is CD25 positive, comprises 5–10%
of normal CD4+ T lymphocytes with the majority thought to
develop in the thymus soon after birth and are termed ‘natural’
Treg cells (nTeg cells) [1–3]. In addition to CD25, the expression
of a forkhead/winged helix transcription factor called FoxP3 in
thymus-derived nTreg cells is also necessary for nTreg lineage
specification in both humans and mice [1–3]. In humans, X-linked
mutations in FoxP3 alleles causes multi-organ autoimmune disease
called Immunodysregulation polyendocrinopathy and enteropathy
X-linked syndrome (IPEX) [1–4]. However, not all CD4+T cells
with suppressive capacities associated with Treg function emerge
from thymic development. Thus, peripheral CD4+T cells can
acquire a Treg phenotype when encountering cognate or foreign
antigen in the presence of regulatory cytokines such as IL-10 (Tr1)
and TGF-b (Th3), and are referred to as ‘induced’ (iTreg) or
‘adaptive’ Treg cells [1–3]. A major limitation that remains in the
Treg biology field is the isolation of functional Treg subsets with a
definitive marker as traditional Treg cell associated markers are
also expressed transiently on non-regulatory activated T cells (e.g.,
GITR, CD25, CTLA-4, FoxP3) [1–3]. Therefore, determining
if a cell population is genuinely regulatory is contingent on a
functional in vitro assay of T-effector cell suppression.
Treg cells have a diverse TCR repertoire, can regulate immune
responses to both self and foreign antigens and initially found to be
critical in maintaining self-tolerance against autoimmune disorders
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9254[1–3]. More recent in vitro studies though highlight CD25+ CD4+
Treg cells to restrain the vigour of diverse antigen-specific
responses in humans, including those directed against tumours,
parasitic, fungal, bacterial and viral antigens and consequently to
be associated with the inability to clear infection of some
pathogens [1–3,5–6] or mount an effective immune response
following immunization in in vivo murine model systems [7].
However, in HIV infection, Treg cells appear to play-opposing
roles, contingent on disease stage. Both animal and human studies
demonstrate that Treg cell numbers are elevated in the acute stage
of virus infection and could dampen the virus-specific adaptive T-
cell response, which may prevent effective virus clearance [8–11].
Thus, peripheral blood derived CD4 T cells from HIV+ subjects
in the acute stage of infection depleted of autologous Treg cells
proliferated more efficiently and secreted more IFN-gamma when
stimulated with HIV antigens [8,9–11]. However, in the chronic
phase of HIV infection, although CD4+ CD25+ Treg cells have
been shown to suppress both HIV-specific CD8 and CD4 T-cell
functions [12–20], including the secretion of CD8 antiviral soluble
factors [13], the presence of these cells maybe beneficial in
controlling immune activation and subsequent disease progression
[16,17–20]. This is exemplified by an inverse correlation between
Treg cell frequency and immune activation markers (e.g. CD38
and HLA-DR) or clinical markers of disease progression (i.e., low
CD4 cell counts/high viral loads) [16–20]. Similarly, a key
difference between pathogenic and non-pathogenic SIV infection
in the natural host is the level of immune activation and reduced
Treg cell numbers in animals infected with pathogenic SIV
[11,21–22]. An important question that follows and one that is
poorly understood, is whether SIV, or indeed HIV infection, alter
the quality of the Treg response in addition to the overall
circulating numbers of these cells. This study investigates this issue.
We demonstrate CD4+ CD25+ Treg-mediated suppression to be
elevated, rather than compromised, in asymptomatic HIV-
infected subjects with fewer absolute numbers of circulating Treg
cells than control subjects. Elevated suppression was noted to be
due to increased sensitivity of effector CD4 T cells from HIV-
infected subjects to be suppressed, which in-turn was linked to
reduced production of the pro-inflammatory, Treg counter-
regulatory cytokine, IL-17 [see 23], rather than increased Treg
cell potency. This study therefore provides fresh insight to how
enhanced Treg-cell function may compensate for declining Treg
number and thereby help maintain immune homeostasis in
chronic HIV infection.
Results
Potency of Treg-Suppression Is Dependent on Strength
of Stimulus and on Effector:Treg Cell Ratio
To reduce potential assay variation arising from varying ratios
of memory versus naı ¨ve CD4 effector cells in the suppression assay
due to the selective loss of CD4+CD45RO+ memory cells in HIV
infection, we isolated .95% pure effectors and Treg cells based on
differential CD25 expression from within the CD4+CD45RO+
T-cell compartment (Fig. 1A). Culture conditions were optimised
to identify the minimum number of CD4+CD45RO+CD252
effector cells that consistently proliferated to mitogenic CD3/28
bead stimulation. A matrix comprising a sliding scale of effec-
tor cell number and concentration of stimulus was optimised.
Figure 1B shows CD3/28 dose dependent effector cell prolifer-
ation as measured by tritiated thymidine incorporation. The mean
count per minute (CPM) in cultures from 27 healthy volunteers
was 27237 and 8282 at 2:1 (high) and 0.2:1 (low) CD3/28 bead:
cell ratio respectively compared to a CPM of 59 in the no
stimulation control. In contrast purified Treg cells were consis-
tently anergic (Fig 1C). Fig 1D shows that at the higher CD3/28
stimulation dose (2:1 bead:effector cell ratio) percent suppression
Figure 1. Potency of Treg-suppression is dependent on
strength of stimulus and on Effector:Treg cell (E:T) ratio. (A)
Typical FACS plot displaying purity of effector (CD4+CD252) and Treg
(CD4+CD25+) populations in healthy control subjects. (B) Mean counts
per minute (CPM) (+SEM) uptake of tritiated thymidine in CD252
effector T cells from healthy controls (N=27) stimulated with mitogenic
CD3/28 beads at 2:1 and 0.2:1 bead: cell ratios. (C) Mean CPM (+SEM) in
CD252 effectors v CD25+ Treg cells stimulated with mitogenic CD3/28
beads at 2:1 bead: cell ratio. (D) Mean (+SEM) percentage suppression
of effector cell proliferation following activation with CD3/28 beads at
2:1 (closed boxes) and 0.2:1 (open boxes) bead: cell ratios.
doi:10.1371/journal.pone.0009254.g001
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(E:T) cell ratio decreases. However, when the stimulation dose was
reduced, suppression levels were maintained close to 100% even at
the lowest E:T ratio tested. These data confirm the optimised
suppression assay to reflect established principles of Treg function,
dependent on both Treg cell number and signal strength [24–25].
The Quality of Treg Cell-Mediated Suppression Is
Significantly Enhanced in HIV Infection
The suppression assay described above was used to compare the
quality of Treg function HIV infected subjects and control
subjects. First, it was confirmed that effector cells from control and
HIV+ subjects displayed comparable levels of proliferation, both
at the high and low CD3/28 mitogenic bead:cell stimulation ratios
of 2:1 and 0.2:1 (Fig. 2A and 2B respectively). At the higher CD3/
CD28 stimulation dose, overall suppression levels were signifi-
cantly higher in cultures from HIV+ subjects versus controls
(p=0.0047,Kruskal-Wallis). Differences between the two groups
were noted at the lower E:T ratio of 1:0.125 (97.3%64.5 vs
80%627.1, HIV+ v controls respectively, p=0.026, Mann-
Whitney), and 1:0.06 (96.2%65.4 vs 75.4%627.6, HIV+ v
controls respectively, p=0.048, Mann-Whitney) (Fig. 2C). As
would be anticipated, this gain of function effect of elevated
suppression in HIV+ cultures was only evident at the high CD3/
CD28 stimulation dose where suppression levels dropped in
control cultures as Treg number was lowered (Fig 2C) and not at
the lower stimulation dose where high levels of suppression were
maintained in the control group over a wider range of E:T ratios
(Fig 2D). Thus on a per cell basis, higher Treg-mediated
suppressor activity was noted in HIV+ cultures v controls. There
was no apparent correlation between the potency of suppression
and clinical parameters such as patients VL, CD4 count and time
from diagnosis (Table 1).
Treg Cells from HIV+ Subjects Are Potent Suppressors of
Effector Cell IFN-Gamma Expression
In addition to proliferation, Treg cells can suppress effector cell
cytokine expression [1–3]. We examined suppression of a key
Figure 2. Treg cell-mediated suppression is significantly enhanced in HIV infection. 2.5610
3 effector T cells were cultured with two
stimulation doses of CD3/CD28 coated magnetic beads, at bead:cell ratios of 2:1 (A) and 0.2:1 (B). Mean CPM (+SEM) uptake of tritiated thymidine is
shown. Mean (+SEM) percentage suppression of effector cell proliferation in HIV+ (open triangles) v control subjects (closed triangles) tested in
parallel, following activation with CD3/28 beads at 2:1 (N=27 control and 14 HIV+ subjects) (C) and 0.2:1 (N=19 control and 9 HIV+ subjects) (D)
bead: cell ratios is shown. For figures 2(C) and 2(D), the Kruskal-Wallis test was used to determine overall mean differences between groups and only
the significant 2-sided p-value (Fig 2C) shown. The Mann-Whitney test was then used to compare differences between the patient and control groups
at individual E:T ratios in Fig 2C, which highlighted the following significant differences: E:T=1:0.125, p=0.026 and E:T=1:0,06, p=0.048.
doi:10.1371/journal.pone.0009254.g002
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infection, IFN-gamma [26]. To study suppression of effector cells
that selectively produced IFN-gamma, but not IL-2, another key
cytokine that is significantly impaired in HIV infection, we
employed two-colour immunofluorescence to distinguish effectors
that produced one or both cytokines. In keeping with previous
data from our laboratory [27] and elsewhere [26,28] effector cells
from HIV+ subjects had fewer single IL-2, and IFN-gamma/IL-2
double positive cells but preserved single IFN-gamma+ cells
compared to controls (Fig. 3B). The effect of adding Treg cells was
therefore measured on single IFN-gamma+ effectors following
CD3/28 stimulation. Suppression levels were noted to be
significantly higher in HIV+ versus control cultures, especially as
Treg cell number was lowered (p,0.0001, Friedman test, Fig 3C).
At an E:T of 1: 0.001, mean suppression in HIV+ cultures was
46.62% versus 10.16% in controls, p=0.0244, Mann-Whitney. At
an E:T of 1: 0.0001, mean suppression in HIV+ cultures was
27.93% versus 0% in controls, p=0.0188, Mann-Whitney. Of 13
HIV+ subjects tested, 10 subjects were also tested in the
proliferation assay. 9 out of these 10 subjects showed elevated
suppression of both proliferation and IFN-gamma expression
compared to controls, indicating good concordance between the
two suppression assays (Table 1).
Enhanced Suppression in HIV+ Cultures Reflects
Increased Sensitivity of Effectors to be Suppressed Rather
Than an Increase in Suppressive Potency of Treg
We next dissected if enhanced suppression observed in HIV+
cultures reflected increased Treg cell potency or was due to an
increased sensitivity of their effector cells to suppression. This was
examined using a previously described allogeneic cross-over assay
system [29–31]. Fig 4A, 4B compare the ability of Tregs from
healthy controls versus HIV+ subjects to suppress proliferation of
the same allogeneic effector cell population in a paired analysis,
Table 1. Summary of clinical data and Treg-mediated suppression.
Patient
I.D Sex
Age
(Years)
CD4 count
(Cells/ml)
Viral load
(Copies/mm3)
Time since
diagnosis
(Years)
CD4+CD25+
FoxP3 absolute
numbers
Mean suppression
of effector cell
proliferation at 1:0.125
Mean suppression
of effector cell single
IFNc at 1:0.001
006 M 41 470 ,50 3
010 M 42 1065 10969 9 95.92124* 22.4*
013 F 37 362 2032 16 97.28432
020 M 40 629 4350 12 99.21849* 34.6*
031 F 42 647 ,50 5 10.10 99.33171* 15*
033 F 43 495 1573 4 2.69
034 M 37 642 261 8 3.17
036 M 26 501 367 3 99.75747
037 M 53 1033 295 4 23.28 0
039 M 34 594 3572 3 99.27153* 73.9*
042 M 38 793 1692 3 99.3157 1.7
048 M 30 362 2448 7.5 8.65 99.30474* 68.7*
053 M 37 763 11224 8 10.29 99.42773* 34.9*
059 F 31 1239 124 4 49.31 93.30409* 62.5*
063 F 32 406 4109 4 2.23 98.63402
080 M 45 431 5407 8 19.61 98.714* 40.2*
082 M 42 763 710 2 100
083 F 32 461 18779 5 11.77 99.78509
087 M 34 540 6058 7 18.57 0
094 M 47 1199 1646 3.5 82.92561* 14.28*
096 M 45 446 ,40 8
Median 38 594 1692 5 N/A N/A N/A
Range 26–53 362–1238 ,40–18779 2–16
Mean 38.48 659.1 3607 6.048 17.05 97.2997 36.04
S.D. 6.516 269.9 4791 3.467 12.35 4.51 31.87
Controls
Mean N/A N/A N/A N/A N/A 34.03125 80.08 11.69
S.D. 18.65 27.1 16.41
P- value 0.0176 0.0286 0.041
A summary of clinical parameters of all HIV+ subjects studied along with the following functional data is summarised: (i) Absolute CD4+CD25+FoxP3+ Treg cell number
and % specific Treg-mediated suppression of (ii) effector cell proliferation or (iii) single IFN-gamma expression. Effector cells in both suppression assays were stimulated
with 2:1 CD3/28 bead to cell ratio. E:T ratio was 1:0.125 in proliferation assay and 1:0.001 in the IFN-gamma suppression assay. Asterik denotes HIV+ subjects who
showed significantly elevated suppression compared to the mean suppression level noted in control subjects under identical culture conditions in both suppression
assay. For age and gender of controls, refer to materials and methods.
doi:10.1371/journal.pone.0009254.t001
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significant differences were observed demonstrating that Treg’s
from HIV+ subjects do not differ intrinsically in potency compared
to control Tregs. We next compared effector cells from HIV+
subjects versus controls in their ability to be suppressed by a
given population of Treg cells isolated from control subjects in
a paired analysis (Fig 4C, 4D). Data shows effector cells from
HIV+ subjects to be more potently suppressed than those from
controls at both E:T ratios tested. (Mean suppression at E:T
1:0.125=64.23%62.66 in controls versus 89.53%67.318 in
HIV+ patients, and at E:T 1:0.06=47.77%634.07 in controls
versus 86.72613.68 in HIV+ patients). Taken together, these
data demonstrate increased Treg-mediated suppression in chronic
HIV+ infection to be a consequence of increased sensitivity of
effector cells from HIV+ subjects to be suppressed by Treg
cells, rather than an increased suppressive potency of Treg
cells.
Impaired IL-17 Production by Expanded CD4+CD45RO+
CD25-Effector Cells from HIV+ Subjects
We next determined why effector cells from HIV+ patients were
more susceptible to CD4 CD25+ Treg-mediated suppression. As
immunosuppressive Treg-cell function shows a reciprocal rela-
tionship with the pro-inflammatory cytokine IL-17 [23,32,33], we
determined if the increased sensitivity of HIV+ effectors to
suppression was associated with reduced IL-17 production. The
frequency of IL-17+ cells was measured in a standard ICS assay,
with IFN-gamma serving as a positive control for activation. In
keeping with other studies the frequency of IL-17+ CD4 T cells
induced by TCR ligation was consistently low in ex vivo memory
CD4 T cells within PBMCs [34–38], despite good induction of
IFN gamma (Fig 5C). Although there was a trend for a small
reduction in the percentage of IL-17+ cells in HIV+ subjects
within the total memory compartment ex vivo, this did not reach
significance for the number of samples tested within the scope of
Figure 3. Treg cells from HIV+ subjects are potent suppressors of effector cell IFN-c expression. 20610
4 effector T cells were stimulated
with 2:1 CD3/28 bead:effector T cell ratio in the presence or absence of varying numbers of Treg cells. 5mg/ml final brefeldin A was added 2 hours
after addition of stimulus and the cultures maintained for 16 hours, before washing, permeabilisation and staining for IFN-c and IL-2. (A)
Representative FACS plots show frequency of single and double IL-2 and IFN-c+ cells in cultures with and without Treg cells. Paired t-test for
differences between patients and controls in individual cytokines is shown. (B) Comparison of the frequency of single and double IL-2 and IFN-c
positive effector cells in chronic HIV+ patients (white bars, N=18) and healthy controls (black bars, N=13) following CD3/CD28 stimulation in the
absence of Treg cells. (C) Comparison of the potency of suppression of single IFN-c + effector cells in cultures from HIV+ (open triangle) versus control
(closed triangle) subjects is shown. Unzeroed data points are plotted. For Fig 2(C), the Friedman test was used to determine overall mean differences
between control (N=13) and HIV+ (N=13) subjects using balanced data points across all effector: target cell ratios and 2-sided p-value (p,0.0001)
reported. The Mann-Whitney test was then used to compare differences between the patient and control groups at individual E:T ratios and
highlighted the following significant differences: E:T=1:0.01, p=0.04; E:T=1:0,001, p=0.0244 and E:T=1:0.0001, p=0.0188.
doi:10.1371/journal.pone.0009254.g003
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CD252 effector T cells with anti-CD3/IL-2 dramatically in-
creased the frequency of IL-17+ effectors in cultures from both
control and HIV+ subjects, as previously shown [34–35] (Fig 5D),
enabling a further comparison of the capacity to induce IL-17 to
be made. Figure 5D shows that control subjects segregate into two
distinct groups, with 50% individuals (8/16 subjects tested) having
lower frequency of IL-17+ cells than the overall group mean and
50% of subjects forming a separate group of higher IL-17+
responders. Taking this heterogeneity into account, we observed
that 18/20 HIV+ individuals tested (i.e. 90%) had lower frequency
of IL-17+ cells than the control group mean. Therefore the
proportion of HIV+ subjects with low IL-17+ effectors was
significantly higher than that of controls (p=0.0113, Fischer’s
exact test), highlighting a small but significant reduction in IL-17
production by expanded effector cells in HIV+ patients. Other
effector cytokines tested, IFN-gamma, IL-4 and TNF alpha
(Fig 5D) did not differ significantly between the HIV+ v control
groups, indicating that reduced frequency of IL-17+ effectors was
unlikely to reflect global reduction of effector cytokine expression
by effector cells from HIV+ subjects.
Analysis of Treg Quantity: Reduction in Absolute Treg
Cell Number in Chronic HIV Infection
Assessing Treg cell frequency in HIV infection has to factor in
the variable that CD4 T cell numbers decline following HIV
infection. We therefore determined the absolute numbers of
circulating Treg cells based on the CD4 T-cell count of HIV+
subjects at the time of the study. The two common markers used to
define Treg cells are CD25 and FoxP3 (see Figure S1). Fig 6 shows
that the absolute Treg cell number is significantly lower in HIV-
infected versus control subjects. Treg cell defined as CD4+CD25+
(Fig. 6A) or as CD4+CD25+FoxP3+ (Fig. 6C) cells were both 2-
fold lower in HIV+ subjects versus controls. Mean CD4+CD25+
absolute cell numbers were 45.37625.32 cells in patients vs
96.83671.98 in controls; p=0.0187, and mean CD4+CD25+
FoxP3 absolute numbers were 17.056 12.35 in patients vs 34.036
18.65 in controls; p=0.0176. In addition, a positive correlation
between CD4 count and Treg cell number with both markers was
observed (Fig. 6B, p=0.0005, and Fig 6D, p=0.003), further
confirming that Treg-cell frequency modeled CD4 T cell count in
HIV infection. Of 11 subjects studied in total, 7 were also studied
in the functional proliferation assay (Table 1). Data show elevated
Figure 4. Enhanced suppression in HIV+ cultures reflects increased sensitivity of effectors to be suppressed rather than an
increased suppressive potency of Treg cells. 2.5610
3 effector T cells were stimulated with CD3/28 beads at a 2:1 bead: effector T cell ratio with
or without the addition of Treg cells and percentage suppression calculated from three replicate wells. Comparison of the potency of Treg cells from
controls versus patients to suppress a given population of allogeneic control effector cells in a paired analysis (N=6) at two E:T cell ratios of 1:0.125
(A) and 1:0.06 (B) respectively is shown. Comparison of the potency of control versus patients effector cell suppression by a given population of
allogeneic control Treg cells in a paired analysis (N=5) at two E:T cell ratios of 1:0.125 (C) and 1:0.06 (D) respectively is shown.
doi:10.1371/journal.pone.0009254.g004
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(Table 1).
In Vivo Treg Number Decline May Reflect Increased
Susceptibility of Treg Cells to HIV-1 Infection
We next examined whether the loss in Treg cell numbers may
be due to this subset being preferentially targeted by HIV
compared to the CD252 effector population. An in vitro infection
assay was used to determine the intrinsic capacity of these two
subsets to HIV infection. Isolated Treg and effector T cell
populations from healthy volunteers were infected with an X4
HIV-1 strain and productive infection measured 4 days later in
cells that were left un-stimulated or stimulated with CD3/CD28.
Consistent with established data that T-cell activation promotes
HIV infection, we observed significantly higher HIV-1 DNA in
activated versus un-stimulated cells, whether they were effector or
Figure 5. Impaired IL-17 production by IL-2 expanded effector cells from HIV+ subjects. IL-17A, IFN-c, IL-4 and TNFa production was
measured from expanded CD4+CD252 effector cell lines. Cells were expanded over six days with irradiated APC, IL-2 and purified anti-CD3 Ab and
then re-stimulated for 16 hours with PMA/ION in the presence of 5mg/ml brefeldin. (A) Representative FACS plot showing gating strategy in PBMC of
ex vivo IL-17 and IFN-c production after 4 hours of PMA/ION stimulation from a HIV+ patient and healthy control in the presence of brefeldin A. (B)
Representative FACS plots show IL-17 and IFN-c+ CD4+CD252 cell frequency from expanded cells after 16 hr stimulation with PMA/Ionomycin in the
presence of 5mg/ml brefeldin A. (C) Frequency of IL-17 and IFN-c production from ex vivo CD4+CD45RO+ gated cells within PBMC (D). Frequency of
total IL-17 positive cells in expanded CD4+CD45RO+CD252 effector cells from controls (N=16) and HIV+ (N=20) subjects. Group differences were
determined by Fischer’s Exact test and 2-sided p-value reported. (E) Frequency of IFN-c, TNFa and IL-4 positive cells in expanded cell lines from 4
control (black bars) versus 6 HIV+ (white bar) subjects. (F) Differences in these individual cytokines between control v HIV+ samples was assessed by
paired t-test and were non significant.
doi:10.1371/journal.pone.0009254.g005
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and Treg cells compared to unstimulated counterpart cells
respectively (Fig. 7A). Furthermore, activated Treg cells had 2-
fold significantly higher levels of HIV DNA than counterpart
effector cells from the same donor (Fig. 7A) (overall group
differences by Kruskal-Wallis was p,0.0001 and paired t-test of
stimulated CD252 v CD25+ cells was p=0.0106). Unstimulated
Treg versus effector cells did not differ in their infection levels
(Fig. 7A). These data highlight that T-cell activation promotes
preferential HIV infection of Treg cells compared to effector cells,
despite the Treg population being anergic to CD3/28 stimulation
(see Fig 1 for proliferation). To investigate whether this was
reflected in vivo, we isolated circulating CD4+ CD25+ Treg and
CD252 effector cells from HIV+ subjects and determined
endogenous HIV infection levels in these subsets before and after
CD3/28 stimulation. A significant level of inter-donor variation
was observed, with 3/7 individuals tested having higher HIV-
DNA in Treg compared to effector cells (Fig 7B, Pt 1,2,4), whilst a
further 3 subjects showed the converse (Pt 3,5&7), and one patient
(Pt 6) showed no difference in infection levels between the two
subsets. Taken together therefore, there was no clear evidence of
preferential infection of CD25+ Treg cells in vivo, despite in vitro
infection studies highlighting this subset to be intrinsically more
susceptible to HIV infection.
Discussion
The present study was designed to probe the quality of CD25+
Treg cells in chronic HIV infection. Understanding precisely how
Treg cell function may be altered in HIV-infected subjects is of
importance in the context of determining if this increasingly
important subset of CD4 T cells represents a reasonable target for
immune-based therapy in HIV infection, and if such therapy
would be appropriate at all stages of HIV disease. Animal studies
demonstrate that cell-based therapy involving direct injection of
Treg cells ameliorates a wide range of experimental models of
inflammatory and autoimmune diseases [1–3]. The above
question is particularly pertinent in HIV infection where Treg
cells may play opposing roles, being associated with detrimental
outcome in the acute stage by suppressing HIV-specific adaptive
immune responses [8,9–11] but beneficial in the chronic stage by
controlling excessive immune activation [16–20]. These effects of
Treg cells have been linked to fluctuating Treg cell numbers rather
than altered Treg potency; indeed a number of studies have shown
Figure 6. Reduction in absolute Treg cell number in chronic HIV infection. The frequency of Treg cells in HIV+ subjects defined as
CD4+CD25+ (A) and CD4+CD25+ FOXP3+ (C) was first enumerated by immunofluroescence and absolute numbers of these subsets derived based on
absolute CD4 T cell count of each subject. Bars represent mean values with SEM. P-values were calculated using Student’s t test. Correlation between
absolute Treg cell numbers and CD4 T cell count was determined using GraphPad PRISM software. (B) Correlation between CD4+CD25+ number and
CD4 T cell count. (D) Correlation between CD4+CD25+FoxP3+ number and absolute CD4 cell count. P-values were calculated using Spearman’s rho
linear regression.
doi:10.1371/journal.pone.0009254.g006
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chronic HIV-1 infection [12–20]. One study by Kinter et al [12]
described lymph node CD25+ Treg cells to display higher
suppressive activity than peripheral blood Treg cells from the
same donor, irrespective of patients VL or CD4 count, indicating
that Treg cells with the highest suppressive potential may reside in
sites of ongoing virus replication. However, a comparative analysis
of Treg potency in HIV+ versus control subjects and underlying
mechanisms has not been reported. Our study addresses this issue
and both confirms and extends previous data [8,12–20], by
demonstrating Treg-mediated suppression of autologous effector
cell proliferation and IFN gamma expression, to be not just
preserved, but significantly elevated in asymptomatic chronic
HIV-infected- versus control–subjects. Interestingly, suppression of
IFN gamma was noted in HIV+ subjects even at the lowest E:T
ratio 1:0.0001 (1 Treg per 10000 effectors) (Fig. 3C). A possible
explanation for this heightened suppression may be linked to our
data discussed below, showing that effector cells from HIV-
infected subjects are more susceptible to Treg-mediated suppres-
sion. Secondly, it is possible that the mechanism of suppression in
HIV+ cultures may not be exclusively through a classical contact-
dependent mechanism. Both these mechanisms potentially require
fewer Treg cells than classical contact-dependent suppression and
are the subject of on-going investigation.
We present novel data on the mechanisms underlying the
phenomenon of enhanced Treg-mediated suppression in HIV
infection, using methodology previously used to probe Treg
function in autoimmune disorders [29–31]. In mixed cultures of
Treg and effector CD4 T cells, net Treg-mediated suppression
reflects intrinsic suppressive potential of Tregs as well as effector cell
suppressability. The allogeneic cross-over assay has been employed
successfully to dissect these two possibilities by separately testing
effector and Treg cells from a given donor to be suppressed or to
suppress respectively a given populationof Treg v effector cells from
a healthy allogeneic donor [29–31]. The advantage of this assay is
that it enables a functional comparison to be made of Treg cells and
effectors in control versus disease subjects. In lupus nephritis
patients, this assay highlighted the absence of functional changes to
Treg or effector cells in disease [31]. In type 1 diabetes, this assay
demonstrated that reduced Treg-mediated suppression in disease
was due to the effectors being more resistant to suppression, rather
than the presence of defective Treg cells [29]. This study demons-
trates that the phenomenon of elevated Treg-mediated suppression
in HIVinfection is not dueto increased potencyof Treg cells, rather
it reflects increased sensitivity of CD4+ CD252 cells from HIV-
infected subjects to be suppressed by Treg cells. These observations
were consistent in samples taken from multiple patients’ and
controls tested in parallel against multiple allogeneic donor cell
populations (Fig 4A–D).
Given the reciprocal relationship between Treg cells and the key
pro-inflammatory cytokine, IL-17 [23], we explored if reduced IL-
17 production by effector cells from HIV+ subjects could be one
mechanism for their increased sensitivity to Treg-mediated
suppression. Other recent data highlight loss of IL-17+ CD4 T
cells, both in HIV [39–40], and in pathogenic SIV infections
[39,41–42]. IL-17+ CD4 T cell frequency tends to be higher in the
gastrointestinal tract than blood and these cells appear to be
reduced in HIV infection [39]. Loss of blood IL-17+ cells has also
been noted in one study in HIV+ subjects as measured by an
ELISPOT assay [40]. However, using the ICS assay in this study,
only a small reduction in IL-17+ numbers in HIV+ subjects v
controls was observed, which did not reach statistical significance
within the scope of this study. On the other hand, evidence is
provided that the capacity of CD4+CD45RO+CD252 expanded
effector cells to produce IL-17 upon re-stimulation in 18/20 HIV+
subjects tested was significantly reduced than that of control
subjects (Fig 5B). Studies that have examined if Th17+ cells are
preferentially infected and thereby lost in HIV infection do not
however support this contention [39,43]. Another mechanism for
reduced Th17 cell frequency in HIV infection may be due to this
subset being highly prone to cell death. This would be
evolutionarily consistent with a fundamental role of Th17 cells
in immunity, whereby expansion of this subset, like Th1 cells, is
under tight control through AICD and/or apoptosis [44], or IDO-
mediated tryptophan-deprivation [45] or galectin-1 signalling
[46]. It appears that in pathogenic SIV infection, Treg/Th17
Figure 7. Increased susceptibility of Treg cells to in vitro HIV-1 infection. Purified CD4+CD45RO+CD25+ Treg cells and
CD4+CD45RO+CD252 effector T cell populations from 12 healthy volunteers were infected with the HIV-1 X4 NL4-3 strain (MOI 0.1) and cultured
either in IL-2 alone or stimulated with CD3/CD28 beads at 2: 1 bead: effector T cell ratio. 4 days later cells were harvested and HIV-1 LTR DNA levels
determined by qPCR relative to the housekeeping gene beta-actin. (A) Relative copy number (RCN) of HIV-1 LTR copies in resting versus stimulated
Treg and effector cells is shown in a paired analysis. (B) Paired analysis of RCN of HIV-1 LTR from stimulated Treg and effector cells isolated from 7
HIV+ subjects. For Fig 7(A), group comparisons by Kruskal-Wallis non-parametric test resulted in a 2-sided p-value ,0.0001. Paired t-test was then
used to compare CD252 v CD25+ samples; significant difference was noted between stimulated CD252 v stimulated CD25+ samples, p=0.0106.
doi:10.1371/journal.pone.0009254.g007
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IL-17 production associated with increased Treg frequency
correlating with detrimental outcome [41]. Taken together, it is
clear that further studies are needed to elucidate the significance of
IL-17 in HIV infection. It is important to establish whether or not
a significant reduction in the capacity of effector cells to produce
IL-17 upon activation through the T-cell receptor complex can be
validated in cells isolated ex vivo from blood using larger sample
numbers than that used in this study and if a reduction of these
effectors translates to overall reduction in IL-17 affecting Treg/
Th17 balance or is compensated for by IL-17 production by other
cell types. In addition, a direct role for reduced IL-17 contributing
to increased susceptibility of effectors to suppression will require
additional investigation using endogenous IL-17 knock-down and/
or reconstitution strategies. Ongoing studies aim to address these
questions to better understand why effector cells from HIV+
subjects are more prone to Treg-mediated suppression.
Our data on Treg cell numbers is consistent with a number of
other studies showing a fall in circulating Treg number in chronic
HIV infection [16,18,19,47]. Two mechanisms may account for
this phenomenon: (i) preferentially HIV infection [48–51], and/or
(ii) redistribution of Treg cells from blood to sites of active virus
replication [12,15,47,52]. A number of in vitro studies show
preferential infection of Tregs with R5/X4 strains [48–51], which
has been linked to this subset expressing high CCR5 [49] and/or
FoxP3 serving to directly active the HIV-1 LTR [49,50]. In
addition, gp120/CD4 interactions may promote the activation,
expansion and suppressive potential of Treg v effector cells
[15,53,54], by up-regulating expression of the anti-apoptotic factor
BCL-2, thereby prolonging cell survival and infection [15,54]. We
also demonstrate that Treg cells are intrinsically more capable of
supporting HIV infection in vitro compared to CD4+CD252
counterparts. However, we did not find clear evidence of pre-
ferential HIV infection of circulating Treg cells in HIV+ subjects.
One reason for this discrepancy may be linked to HIV-infected
Treg cells not surviving following HIV infection in vivo or
trafficking to tissue sites, as previously shown [12,15,47,52],
thereby confounding ex vivo analysis of virus compartmentalisation
in circulating Treg cells isolated from HIV+ subjects. In support of
this contention, Ji & Cloyd (2009) [54] observed that in vitro
infection of Treg cells leads to the up-regulation of the homing
receptor CD62L and integrin alpha4beta7, and upon injection of
HIV and mock infected Treg cells into SCID mice, infected Tregs
could be found in higher numbers in lymph nodes and lymphoid
tissue. This is also corroborated by data showing correlation of
virus load in HIV-infected subjects with Treg cell increase in the
gut [52], tonsillar tissue [15], and lymph nodes [47], and
normalisation after initiation of HAART [47,52]. Further studies
to elucidate the cellular and molecular mechanisms of Treg versus
effector cell function in HIV infection combined with animal
models that allow the manipulation of Treg cell number in vivo,
may give us a better understanding of the real contribution Treg
cells play in HIV disease progression.
Materials and Methods
Subjects
Peripheral blood samples in EDTA from HIV-infected subjects
were obtained from Guy’s and St. Thomas’ Charity Infectious
Disease Biobank facility. This study was approved by an
independent ethics committee [Ethics reference 06/Q1909/48]
and informed consent obtained from all patients. A total of
19 HIV-infected subjects were studied (see Table 1 for clinical
details). All patients enrolled in this study were diagnosed as being
HIV infected for at least two years prior to the study, they were
treatment naı ¨ve with a stable CD4 count, as measured on at least
two occasions (from time of diagnosis and at six-twelve monthly
intervals) prior to sampling. Median infection time in years since
diagnosis was 5 (range 3–16 years). Median CD4 count was 594
cells/mm
3 (range 362–1239) and therefore within the normal
range of CD4 count (300–1500 cells/mm
3) observed in healthy
controls [55]. 3/19 patients studied had undetectable viral loads
(VL). Median VL was 1692 RNA copies/ml (range,40–18,779).
Control HIV seronegative blood samples were either purchased
from the National Blood Transplantation Service at St George’s
Hospital Tooting, UK or obtained through the Infectious Disease
Biobank and tested in parallel with samples from HIV+ subjects.
Where information was available, control subjects were matched
as closely as possible in terms of age with that of patients, and
attempts were also made to match these groups in terms of gender.
The mean and median ages of the HIV positive volunteers were
38.5 years and 38 years respectively and for the healthy controls
were 28.6 years and 26 years respectively. The gender matching
proved practically difficult because of the nature of the gender of
the volunteers who came forward; whereas 71.5% of the HIV
positive participants were male, the corresponding figure for the
healthy volunteers was 12.5%.
Cell Separation
Peripheral blood mononuclear cells (PBMC) were isolated by
density gradient centrifugation (Lymphoprep: Axis-Shield PoC
AS, Oslo, Norway). CD4+CD252 and CD4+CD25+ cell
populations were isolated using Dynabeads T regulatory cell
isolation kit (Invitrogen, UK) following manufacturers instructions.
Briefly, CD4+CD45RO+ T cells were isolated from PBMC by
negative selection. 10
8 PBMCs were first incubated for 20 minutes
at 4uC with 200ul of an antibody cocktail directed against non-
CD4 T-cell PBMC subsets plus purified CD45RA antibody 10
8
PBMCs/1ml (eBioscience, San Dieago, CA, USA). Excess
antibody was washed off and cells resuspended at 10
8/2ml
PBMCs in PBS/2%HS and 10
8/1ml PBMC of immunomag-
netic beads were added at room temperature for 20 minutes.
Cells bound to the beads were removed on a magnet and the
non-bead fraction confirmed by immunostaining to be .95%
CD4+CD45RO+. CD25+ cell fraction (Treg) was subsequently
isolated from CD4+CD45RO+ cells using 10
6/10ml cells of mouse
anti-human CD25+ positive selection beads at 4uC for 25 minutes.
Tregs were detached from the positive selection beads at room
temperature for 45 minutes using Detach-a-bead. CD252
fraction (effector population) was isolated by negative selection
from the remaining CD4+CD45RO+ fraction with the addition of
10
6/50ml cells of CD25+ positive selection Dynabeads at room
temperature for 40 minutes. The purity of each population was
examined using monoclonal antibodies (mAbs) against CD4,
CD45RO, CD25, and FoxP3. Purities were routinely .95%.
Treg Suppression Assay as Measured by Suppression of
Effector Cell Proliferation
All assays were carried out in RPMI-1640 Glutamax 25mM
HEPES media (Invitrogen, Paisley, UK), 10% human AB serum
(Lonza, Sweden), and supplemented with 20mg/ml Gentamycin
(Sigma-Aldrich, UK). Suppression assays were conducted by
plating 2.5610
3 CD4+CD252 effector cells per well in a 96 well
plate with varying ratios of CD4+CD25+ Treg cells (Effector: Treg
ratio), 1:0.5, 1:0.25, 1:0.125, 1:0.06, serially diluted to 1:0.003).
Cells were stimulated with two ratios of Dynal anti-human CD3/
CD28 coated magnetic beads (bead: effector cell ratio, 2:1 and
0.2:1) (Invitrogen, Paisley, UK). Assays were set up in triplicate.
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of (
3H)-thymidine (GE Healthcare, UK) for the last 16 hours
of culture. Cell proliferation was assessed by uptake of (
3H)-
thymidine by processing samples through a cell harvester (Perkin-
Elmer, UK). 3H- thymidine uptake was measured as counts per
minute (CPM) on a Betacounter (Perkin-Elmer, UK). Percentage
suppression was calculated as 100-(counts per minute (cpm) of co-
cultures/cpm of effectors alone) 6100).
Treg Suppression Assay as Measured by Suppression of
Effector Cytokine Expression
20610
3 CD4+ CD252 effector cells were cultured in 96-well
plates with varying ratios of CD4+CD25+ Tregs (effector: Treg
ratios, 1:0.1, 0:0.01, 1:0.001 and 1:0.001) and stimulated with 2:1
(bead: effector cell) anti-human CD3/CD28 coated magnetic
beads (Invitrogen, Paisley, UK). 5mg/ml of Brefeldin A (Sigma-
Aldrich, UK) was added 2 hours post-stimulation. Cultures were
maintained for 16 hours before intracellular staining (ICS) for
Interferon-gamma (IFN-gamma) and Interleukin-2 (IL-2). ICS was
performed once the cells had been washed twice with cold wash
buffer (PBS 2% FCS, Invitrogen, Paisley, UK). A cell fixing and
permeabilisation kit (AbD Serotec, Oxford, UK) was used
according to manufacturer’s instructions. Briefly, cells were fixed
using 100ml of solution A (fixation buffer) for 20 minutes at RT,
then washed and resuspended in 45ml of solution B (permeabilisa-
tion buffer) plus 5ml FCS (Gibco, Invitrogen, UK) with 5ml each
PE-labelled anti human IFN-gamma, APC-labelled anti human
IL-2, or the appropriate isotype control mAbs for 60 minutes at
room temperature. Samples were washed 63 and resuspended in
fixation buffer (PBS, 4% formaldehyde) and acquired using BD
FACSDiva software (Becton Dickson, UK) on a Becton Dickson
FACSCanto II fluorescence activated cell sorter (Becton Dickson,
UK). A minimum of 30–50,000 events were acquired for analysis.
Analysis was performed using FlowJo software (Treestar Inc.,
Ashland, OR, USA). Percent suppression was calculated as
detailed in section above.
IL-17 Detection
For ex vivo detection of IL-17 in PBMCs, PBMCs were
stimulated with 10ng/ml PMA and 1mg/ml Ionomycin (Io)
(Sigma-Aldrich, UK) for 4 hours in the presence of 5mg/ml
Brefeldein A. ICS staining was performed as described above
following surface staining with CD3 (APC labelled, BD Pharmin-
gen), CD8 (PE-CY5 labelled Pharmingen) and CD45RO
antibodies (PE labelled, BD Pharmingen). For detection of IL-17
in expanded effector cells 0.5610
6 purified CD4+ CD45RO+
CD252 effector cells were cultured at a ratio of 0.5:1 with
irradiated mixed donor PBMCs in the presence of 30IU/ml IL-2
and 1mg/ml purified soluble anti-human CD3 (eBioscience, UK).
On day 6 post expansion, effector cells were re-stimulated
overnight with 10ng/ml PMA (Sigma-Aldrich,UK) and 1mg/ml
Ionomycin (Sigma- Aldrich,UK) in the presence of 5mg/ml
Brefeldin A (Sigma- Aldrich,UK). IL-17 (FITC labelled IL-17A,
eBioscience) and IFN-gamma (PE-labelled), IL-4 (PE-labelled),
TNFa (FITC-labelled) cytokine measurement was performed as
described above by a standard ICS assay.
Enumerating Treg Cells by Cell Surface Markers
The frequency of Treg cells was determined using a
combination of established markers in purified PBMC fractions.
FoxP3 expression was determined using APC anti-human FoxP3
staining set (Clone PCH101, eBioscience, San Dieago, CA, USA)
as per manufacturer’s instructions. Briefly, after washing cells with
cold wash buffer, (PBS Gibco Invitrogen, UK, 2% FCS Gibco
Invitrogen, UK) cells were first surface stained with FITC-labelled
CD4 (clone SK3 BD Pharmingen, UK) and PE-labelled CD25
(clone MEM-181, AbD Serotec, Oxford, UK) at 4uC for
30 minutes. Cells were then washed and fix/permeabilised at
4uC for 60 minutes using Fix/Permeabilization concentrate and
diluent. APC-labelled FoxP3 (clone PCH101, eBioscience, San
Dieago, CA, USA) was incubated for a further 30 minutes.
Flurochrome conjugated isotype control antibodies were included
to define specific staining. Samples were acquired on Becton
Dickson FACs Calibur machine and data analysed using
CellQuest software. Lymphocytes were gated based on FSC/
SSC and Treg cell markers CD25 and FoxP3 were determined
within the CD4 gate. Absolute numbers of Treg cells were
determined as the percentage of cells staining for defined Treg cell
markers multiplied by the absolute CD4 T-cell count of the patient
at the time of sampling.
HIV-1 Virus Stocks
Full length HIV infectious virus was produced by standard
transient transfection of 293T cells with purified proviral DNA
encoding the HIV-1 molecular clone NL4-3 (kind gift of M.
Malim). 293T cells were grown in D-MEM (Gibco, Invitrogen,
UK) 10% FCS (Gibco, Invitrogen, UK) 20mg/ml Gentamycin
(Sigma-aldrich, UK). Transfection was performed using Fugene6
transfection reagent (Roche, UK). Culture supernatant was
harvested 72 hours after transfection, clarified by centrifugation,
and stored at 280uC. Negative control included virus-free culture
supernatant from 293T cultures. Virus stocks were standardised
on the basis of HIV-1 Gag p24 concentration measured by ELISA
(NCI Frederick, HIV-1 p24 Antigen Capture Assay Kit) and by
assessing virus titre in a standard infectivity assay using CEM G37
indicator cells which express green fluorescent protein (GFP) upon
productive infection (kind gift Dr P Kellam, University College
London). The number of infectious virus particles per ml was
determined based on GFP expression induced per ml of virus
stock [56].
In Vitro HIV Infection
CD4+CD252 effector and counterpart CD4+CD25+ Treg cell
populations were isolated from healthy HIV uninfected control
volunteers. Equivalent numbers of effector and Treg cells were
cultured with serial dilutions of NL4-3 virus stock, starting at a
multiplicity of infection (MOI) of 0.1 based on virus stock titre.
Effector and Treg fractions were cultured separately either with or
without stimulation with anti human CD3/CD28 coated-magnetic
for 4 days. Magnetic anti-CD3/CD28 coated beads (Dynabeads,
Invitrogen, UK) were removed by placing on a magnet before cells
were washed twice in cold PBS (Invitrogen, UK), pelleted and
stored at 280uC until DNA extraction.
Quantitative Real-Time PCR for HIV DNA
DNA was extracted using Qiagen DNeasy kit as per
manufacturer’s instructions. Briefly, cell pellets were resuspended
in 200ul PBS (Invitrogen, UK), 20ml of Proteinase K solution, and
then lysed in 200ul of lysis buffer at 56uC for 10 minutes. 200ul of
100% ethanol was then added and spun in a DNeasy spin column
to retain DNA. After two wash steps, DNA was eluted in 80ul of
kit elution buffer and stored at 220uC until analysis. For ex vivo
HIV LTR detection from HIV-infected patient blood, extracted
DNA had to be amplified first using a complete whole genome
amplification kit (Sigma-Aldrich, UK) due to small cells numbers.
HIV LTR DNA was measured relative to the house-keeping gene
beta-actin using Quantitect SYBR green PCR kit (Qiagen, UK).
Treg Quality in HIV Infection
PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9254All assays were performed on an ABI Prism 7000 machine
(Applied Biosystems, CA, USA). Primer sequences for HIV-1 LTR
detection [57] by SYBR green was as follows: L2: CTG-
TGGATCTACCACACACAAGGCTAC. L3: GCTGCTTAT-
ATGTAGCATCTGAGGGC.
Cycling conditions were 40 cycles as follows: 50uC for 2 mins,
95uC for 15 mins, 95uC for 25 seconds, 60uC for 30 seconds, then
72uC for 30 seconds. A disassociation step was introduced. Data
was aquired on a SDS2.3 (Applied biosystmes, CA,USA) and
analysed relative to beta-actin. Relative copy number was
calculated by first determining the delta ct (gene of interest minus
housekeeping gene) and then using the equation, relative copy
number (RCN)=POWER(2,-delta).
Statistical Analysis
Statistical analysis was performed using Graphpad PRISM
software (Graphpad Prism Inc., version 4, CA, USA). When more
than two groups were compared, an ANOVA was performed to
assess overall variation. Where the ANOVA indicated a significant
(p,0.05) difference, further tests were performed to determine
where the differences lay. For comparison of two groups, either a
non-parametric Mann-Whitney test or a paired t-test for paired
samples was employed. All p-value reported are two-sided.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0009254.s001 (0.16 MB TIF)
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